期刊文献+

非特异性T细胞疫苗对空肠弯曲菌诱导的SLE样综合征小鼠免疫功能的影响 被引量:1

The effects of non-specific T cell vaccination on immune function of systemic lupus erythematosus-like mouse model induced by campylobacter jejuni
原文传递
导出
摘要 目的探讨非特异性T细胞疫苗(TCV)对空肠弯曲菌诱导的系统性红斑狼疮(SLE)样综合征小鼠免疫功能的影响。方法采用甲醛化空肠弯曲菌CF-1株辅以佐剂诱导近交系BALB/c小鼠SLE样自身免疫综合征病理模型,然后用非特异性TCV对该病理模型进行治疗。用酶联免疫吸附试验(ELISA)法检测小鼠血清抗dsDNA抗体、抗空肠弯曲菌CF-1外膜蛋白(CF-OMP)抗体水平,并检测特异性迟发型超敏反应(DTH),用苏木素-伊红(HE)染色检测肾脏病损。结果①非特异性TCV一方面使模型鼠抗dsDNA抗体水平升高,另一方面却使血清抗CF-OMP抗体水平一定程度的降低;②非特异性TCV明显抑制CF-1模型鼠对空肠弯曲菌特异性的DTH反应;③非特异性TCV能部分减轻模型鼠的肾脏病损。结论非特异性TCV对模型鼠的体液免疫和细胞免疫均有抑制作用。 Objectives To study the effects and pathogeneic mechanism of non-specific T cell vaccination (TCV) on immune function of systemic lupus erythematosus (SLE)-like mouse model induced by campylobacter jejuni. Methods SLE-like mouse model was established by immunizing syngeneic mouse BALB/C with campylobacter jejuni strain CF-1, and then treated with non-specific TCV. Results The chara-cteristics of mouse model induced by CF-1 were high level serum autoantibodies against dsDNA and CF-OMP, enhanced DTH reaction and polyorganic inflammatory injury. The immunized mice can be treated by non-specific TCV. The results demonstrated that serum specific anti-CF-OMP antibodies were decreased and DTH reaction was suppressed and kidney injury was partially recovered. Conclusions Non-specific TCV can suppress both humoral and cellular immune function.
出处 《中华风湿病学杂志》 CAS CSCD 2004年第10期601-603,641,共4页 Chinese Journal of Rheumatology
关键词 非特异性 空肠弯曲菌 T细胞疫苗 SLE 小鼠 综合征 免疫功能 结论 水平 目的 Vaccines T-lymphocytes Campylobacter, jejuni Lupus erythematosus, systemic
  • 相关文献

参考文献11

  • 1李博,叶志中,庄俊汉.系统性红斑狼疮治疗研究的进展[J].中华风湿病学杂志,2004,8(1):46-50. 被引量:22
  • 2Cohen IR, Ben-Nun A. Vaccination against autoimmune encephalomyelitis (EAE): attenuated autoimmune T lymphocytes confer resistance to induction of active EAE but not to EAE mediated by the intact T lymphocyte line. Eur J Immunol, 1981, 11: 949-952.
  • 3Kakimoto K, Hara H. T cell vaccination-induction of anti-idiotypic immune response against TCR and shift of Th1/Th2 balance. Nippon Rinsho, 1997, 55: 1512-1518.
  • 4Horsfall AC, Howson R, Silveira P, et al. Characterization and specificity of B-cell responses in lupus induced by Mycobacterium bovis in NOD/Lt mice. Immunology, 1998, 95: 8-17.
  • 5Urbanek-Ruiz I, Ruiz PJ, Steinman L, et al. Immunomodulatory vaccination in autoimmune disease. Endocrinol Metab Clin North Am, 2002, 31: 441-456.
  • 6Benoist C, Mathis D. Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry. Nat Immunol, 2001,2: 797-801.
  • 7Singh RR. The potential use of peptides and vaccination to treat systemic lupus erythematosus. Curr Opin Rheumatol, 2000, 12:399-406.
  • 8刘晓华,柯瑶,沈友轩,王玲,季晓辉.应用趋化因子受体标记对系统性红斑狼疮患者Th细胞亚群改变及其意义的初步研究[J].中华风湿病学杂志,2004,8(1):23-26. 被引量:2
  • 9汤建平,顾越英,沈南.Ⅰ型干扰素在系统性红斑狼疮发病机制中的作用[J].中华风湿病学杂志,2004,8(4):240-244. 被引量:9
  • 10贾永峰 力弘 张建平.雷公藤多甙对空肠弯曲菌诱导的自身免疫鼠的治疗研究[J].中国药学,2000,9:155-157.

二级参考文献34

  • 1Van Brubben MC J, Wrlgrcen B, Rijke RPM, et al. Heparin and heparinoids prevent the binding of immune complexes containing nuclesomal antigens to the GBM and delay nephritis in MRL/lpr mice. Kidney Int ,1996, 50:1555-1564.
  • 2Wang Y,Hu O,Madre JA.Amelioration of lupus-like autoimmune disease in NZB/W F 1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci USA, 1996, 93:8563-8568.
  • 3Charles PJ, Smeenk RJT, Dejong J, et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha:findings in open-label and randomiz
  • 4Sato EI,Assis LS,Lourenzi VP,et al. Long-term thalidomide use in refraetory cutaneous lesions of systemic lupus erythermatosus. Rev Assoc Med Bras, 1998,44:289-293.
  • 5Clynes R,Dumitru C,Ravetch JV.Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science, 1998,279:1052-1054.
  • 6Balomenos D,Rumold R,Theofilopoulos AN.Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice.J Clin Invest, 1998,101:364-371.
  • 7Alvarez NYJ, Cobrarrubias CA, Escalante TF, et al. Bromocriptine in systemic lupus erythematosus: a double-blind randomized, placebo-controlled study. Lupus ,1998, 7:414-419.
  • 8Van Vollenhoven RF, Park JL, Genovese MC, et al. A double-blind,placebo-controlled, clinical trial of dehydrcepiandrosterone in severe systemic lupus erythematosus. Lupus, 1999,8:181 - 187.
  • 9Blanco R, Martinez VM, Redriguezvalverde V, et al. Successful therapy with danazol in refractory autoimmune thrombocytopoenia associated with rheumatic diseases. Br J Rheumatol,1997, 36:1095-1099.
  • 10Levy Y, Sherer Y, Ahmed A, et al. A study of 20 SLE patients with intravenous immunoglobulin - clinical and serologic response. Lupus,1999, 8:705-712.

共引文献30

同被引文献18

  • 1穆荣,戴振鹏,栗占国,高晓明.T细胞疫苗治疗系统性红斑狼疮的初步临床研究[J].中华内科杂志,2004,43(8):568-571. 被引量:7
  • 2Llorente L,Richaud-Patin Y,Garcia-Padilla C,et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum,2000,43:1790-1800.
  • 3Cunnane G,Chan OT,Cassafer G,et al. Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide. Arthritis Rheum,2004,50:1539-1548.
  • 4Quezada SA,Eckert M,Adeyi OA,et al. Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis. Arthritis Rheum,2003,48:2541-2554.
  • 5Davis JC,Totoritis MC,Rosenberg J,et al. Phase Ⅰ clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol,2001,28:95-101.
  • 6Grammer AC,Slota R,Fischer R,et al. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest,2003,112:1506-1520.
  • 7Kalunian KC,Davis JC Jr,Merrill JT,et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized,double-blind,placebo-controlled trial. Arthritis Rheum, 2002,46:3251-3258.
  • 8Looney RJ,Anolik J,Sanz I. Treatment of SLE with anti-CD20 monoclonal antibody. Curr Dir Autoimmun,2005,8:193-205.
  • 9Leandro MJ,Edwards JC,Cambridge G,et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum,2002,46:2673-2677.
  • 10Leandro MJ,Cambridge G,Edwards JC,et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology,2005,27: 1462-1479.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部